[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576757":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":36,"locations":42,"responsibleParty":95,"collaborators":32,"id":97,"slug":32,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":98,"sex":104,"minAge":105,"maxAge":32,"enrollmentInfo":106,"targetDuration":32,"studyType":109,"phases":110,"briefSummary":113,"conditions":114,"keywords":124,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"BlueRock Therapeutics","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","OpCT-001 dose level 1 will be administered via subretinal injection.",[13],"Biological: OpCT-001",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","OpCT-001 dose level 2 will be administered via subretinal injection.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3 (optional)","OpCT-001 dose level 3 will be administered via subretinal injection.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","OpCT-001 dose level 4 will be administered via subretinal injection.",[13],[27,33],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","OpCT-001","Cell therapy product composed of photoreceptor precursor cells derived from human induced pluripotent stem cells (iPSCs).",[9],null,{"type":28,"name":29,"description":34,"armGroupLabels":35,"otherNames":32},"Cell therapy product composed of photoreceptor precursor cells derived from human iPSCs.",[15,19,23],[37],{"name":38,"role":39,"phone":40,"phoneExt":32,"email":41},"Patient Engagement","CONTACT","1-877-380-3931","clinicaltrials@bluerocktx.com",[43,59,71,83],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of Miami, Bascom Palmer Eye Institute","RECRUITING","Miami","Florida","33136","United States",{"type":51,"coordinates":52},"Point",[53,54],-80.19366,25.77427,{"lat":54,"lon":53},[57],{"name":38,"role":39,"phone":58,"phoneExt":32,"email":41},"877-380-3931",{"facility":60,"status":45,"city":61,"state":62,"zip":63,"country":49,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Mid Atlantic Retina\u002F Wills Eye","Philadelphia","Pennsylvania","19107",{"type":51,"coordinates":65},[66,67],-75.16362,39.95238,{"lat":67,"lon":66},[70],{"name":38,"role":39,"phone":58,"phoneExt":32,"email":41},{"facility":72,"status":45,"city":73,"state":74,"zip":75,"country":49,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Retina Foundation of the Southwest","Dallas","Texas","75231",{"type":51,"coordinates":77},[78,79],-96.80667,32.78306,{"lat":79,"lon":78},[82],{"name":38,"role":39,"phone":58,"phoneExt":32,"email":41},{"facility":84,"status":45,"city":85,"state":86,"zip":87,"country":49,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"University of Wisconsin","Madison","Wisconsin","53705",{"type":51,"coordinates":89},[90,91],-89.40123,43.07305,{"lat":91,"lon":90},[94],{"name":38,"role":39,"phone":58,"phoneExt":32,"email":41},{"type":96,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100576757",false,"NCT06789445","A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)","A Phase 1\u002F2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease","CLARICO","Key Inclusion Criteria:\n\n* Confirmed genetic diagnosis of primary photoreceptor (PR) disease\n* Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.3. BCVA at Screening for Phase 2: ETDRS letter score between 20 to 60, inclusive.\n* Retinal structure examination in the study eye demonstrating regions suitable for cell administration.\n\nKey Exclusion Criteria:\n\n* Clinically relevant, active ocular inflammation or infection\n* Glaucoma or other significant optic neuropathy\n* Diabetic macular edema or diabetic retinopathy\n* Clinically significant cystoid macular edema\n* In phakic participants: Spherical equivalent refractive error of greater than 8.00 diopters myopia\n* Ocular surgery ≤3 months before Screening\n* Monocular vision (ie, no light perception in the fellow eye)\n* Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated.\n* Any current and active infection (bacterial\u002Fviral\u002Ffungal) that could put the participant at risk from immunosuppression\n* History of any cell therapy, gene therapy, or retinal implant at any time\n* Previously received a bone marrow or solid organ transplant","ALL","18 Years",{"count":107,"type":108},54,"ESTIMATED","INTERVENTIONAL",[111,112],"PHASE1","PHASE2","Study OpCT-001-101 is a Phase 1\u002F2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.",[115,116,117,118,119,120,121,122,123],"Primary Photoreceptor Disease","Retinitis Pigmentosa (RP)","Usher Syndrome","Inherited Retinal Disease (IRD)","Rod-Cone Dystrophy","Rod-Cone Disease","Retinal Degeneration","Cone-Rod Disease (C-RD)","Cone-Rod Dystrophy",[102,125,126,127,117,128,129,130,131,132],"Photoreceptor cells","Cell Therapy","Cellular Therapy","Retinitis Pigmentosa","Inherited retinal disease (IRD)","Primary Photoreceptor disease (PPD)","Rod-Con Disease (R-CD)","Cone-Rose disease (C-RD)","2026-04-07",{"date":135,"type":136},"2026-04-13","ACTUAL",{"date":138,"type":136},"2025-03-10",{"date":140,"type":108},"2030-10",{"name":5,"class":6},4]